title: A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.
abstract: OBJECTIVE
  The important role of serotonin-1A (5-hydroxytryptamine-1A [5-HT(1A)]) receptors in cognition, behavior, and drug response is increasingly being recognized. Postmortem studies suggest decreased 5-HT(1A) receptors in patients with Alzheimer disease (AD), but this has not been confirmed in vivo. Our primary objective was to assess the extent of 5-HT(1A) receptor losses in mild to moderate AD.
  
  
  METHODS
  The authors examined 5-HT(1A) receptors in 10 patients with mild to moderate AD and 10 healthy volunteers with the same sex and similar age using positron emission tomography imaging with the selective 5-HT(1A) receptor radioligand, [(11)C]WAY-100635. Regions of interest (ROIs) were manually drawn on coregistered magnetic resonance images for the frontal, lateral temporal, medial temporal (MTC), parietal, and cerebellar cortices. Using the simplified reference tissue model, 5-HT(1A) binding potentials (BPs) were calculated relative to the cerebellum.
  
  
  RESULTS
  After adjusting for partial volume effects, ROI analysis showed a significant group effect (AD versus comparison group) on BP. Analysis of between-subjects factors showed significantly decreased 5-HT(1A) BP in the right MTC, but not in the other ROIs.
  
  
  CONCLUSIONS
  Given the strategic role of these receptors, loss of right medial temporal 5-HT(1A) receptors might play an important role in AD symptomatology.
authors.affiliation: Neuropharmacology Research Program and Geriatric Psychiatry, Toronto, Ontario, Canada. Krista.Lanctot@sunnybrook.ca
authors.forename: Krista L
authors.initials: KL
authors.lastname: Lanctôt
authors.forename: Doug F
authors.initials: DF
authors.lastname: Hussey
authors.forename: Nathan
authors.initials: N
authors.lastname: Herrmann
authors.forename: Sandra E
authors.initials: SE
authors.lastname: Black
authors.forename: Pablo M
authors.initials: PM
authors.lastname: Rusjan
authors.forename: Alan A
authors.initials: AA
authors.lastname: Wilson
authors.forename: Sylvain
authors.initials: S
authors.lastname: Houle
authors.forename: Nicole
authors.initials: N
authors.lastname: Kozloff
authors.forename: Nicholaas Paul L G
authors.initials: NP
authors.lastname: Verhoeff
authors.forename: Shitij
authors.initials: S
authors.lastname: Kapur
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000378:metabolism*; D002250:Carbon Radioisotopes; D002525:Cerebellar Cortex / Q000000981:diagnostic imaging* / Q000378:metabolism*; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data; D008297:Male; D010879:Piperazines; D049268:Positron-Emission Tomography / Q000706:statistics & numerical data*; D011569:Psychiatric Status Rating Scales; D011725:Pyridines; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D012720:Severity of Illness Index; D013702:Temporal Lobe / Q000000981:diagnostic imaging / Q000378:metabolism
chemical_list: D002250:Carbon Radioisotopes; D010879:Piperazines; D011725:Pyridines; D044282:Receptor, Serotonin, 5-HT1A; D012701:Serotonin; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide